MedDataX Logo

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

NCT ID: NCT00051558

Last Updated: 2009-03-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

428 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-11-30

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Osteoporosis is a condition in which the amount of bone is reduced, the bones are weak, and there is an increased risk for fractures. Glucocorticoids (such as prednisone) are prescribed to treat a large number of conditions such as arthritis and asthma. When taken for several months or longer, glucocorticoids can cause bone loss and lead to a form of osteoporosis called "glucocorticoid-induced osteoporosis." This study compared the effects of teriparatide, the study drug, with alendronate, an approved drug for treating glucocorticoid-induced osteoporosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCT00079924

Postmenopausal Osteoporosis
COMPLETED PHASE4

Bone Effects of Teriparatide Following Alendronate

NCT00191893

Osteoporosis
COMPLETED PHASE3

Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis

NCT00503399

Osteoporosis
COMPLETED PHASE3

The Forteo Alendronate Comparator Trial

NCT02416271

Osteoporosis
COMPLETED PHASE4

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

NCT00887354

Osteoporosis
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Teriparatide 20 micrograms/day injection plus oral placebo, 36 months

Group Type EXPERIMENTAL

Teriparatide

Intervention Type DRUG

20 micrograms/day, injection, 36 months

Placebo

Intervention Type DRUG

Oral placebo, daily, 36 months

B

Alendronate 10 mg/day oral plus injection placebo, 36 months

Group Type ACTIVE_COMPARATOR

Alendronate Sodium

Intervention Type DRUG

10 mg/day, oral, 36 months

Placebo

Intervention Type DRUG

Injection placebo, daily, 36 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Teriparatide

20 micrograms/day, injection, 36 months

Intervention Type DRUG

Alendronate Sodium

10 mg/day, oral, 36 months

Intervention Type DRUG

Placebo

Oral placebo, daily, 36 months

Intervention Type DRUG

Placebo

Injection placebo, daily, 36 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY333334 Forteo Forsteo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women age 21 years or older
* Taking on average 5.0 mg/day prednisone or equivalent for at least 3 months prior to screening

Exclusion Criteria

* Taking bisphosphonates within past 6 months
* More than 30 micrograms/day of estradiol or equivalent in past 3 months
* History of alcoholism or drug abuse in past year
* Pregnant women or nursing mothers
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eli Lilly

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Loma Linda, California, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Palo Alto, California, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Aurora, Colorado, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Fargo, North Dakota, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Jamestown, North Dakota, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Milwaukee, Wisconsin, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Graz, , Austria

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Vienna, , Austria

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Brussels, , Belgium

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Ghent, , Belgium

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Leuven, , Belgium

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Aarhus, , Denmark

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Oslo, , Norway

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Carolina, , Puerto Rico

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Ponce, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Belgium Denmark Norway Puerto Rico

References

Explore related publications, articles, or registry entries linked to this study.

Saag KG, Agnusdei D, Hans D, Kohlmeier LA, Krohn KD, Leib ES, MacLaughlin EJ, Alam J, Simonelli C, Taylor KA, Marcus R. Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. Arthritis Rheumatol. 2016 Sep;68(9):2122-8. doi: 10.1002/art.39726.

Reference Type DERIVED
PMID: 27111239 (View on PubMed)

Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol. 2010 Jan;37(1):141-8. doi: 10.3899/jrheum.090411. Epub 2009 Nov 16.

Reference Type DERIVED
PMID: 19918047 (View on PubMed)

Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007 Nov 15;357(20):2028-39. doi: 10.1056/NEJMoa071408.

Reference Type DERIVED
PMID: 18003959 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B3D-US-GHBZ

Identifier Type: -

Identifier Source: secondary_id

6484

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
NCT00005006 COMPLETED PHASE2
Teriparatide Treatment in Patients With Inherited Osteoporosis
NCT01360424 COMPLETED PHASE4
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
NCT00670501 COMPLETED PHASE3
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
NCT01753856 COMPLETED PHASE4
Cyclic Versus Daily Teriparatide on Bone Mass
NCT00668941 UNKNOWN PHASE2
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
NCT00035256 COMPLETED PHASE4
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
NCT00504166 COMPLETED PHASE4
2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
NCT00191425 COMPLETED PHASE4
Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis
NCT00542984 COMPLETED PHASE3
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
NCT00046137 COMPLETED PHASE3
PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
NCT00005005 COMPLETED PHASE2
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
NCT00092014 COMPLETED PHASE3
Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
NCT00239629 COMPLETED PHASE4
Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
NCT00532207 COMPLETED PHASE3
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
NCT01750086 COMPLETED PHASE4
Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide
NCT02195895 COMPLETED PHASE2
The Effects of Alendronate After Cure of Primary Hyperparathyroidism
NCT00359385 WITHDRAWN PHASE4
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
NCT00927186 COMPLETED PHASE4
Teriparatide (PTH) and Bone Strength in Postmenopausal Women
NCT01155245 UNKNOWN
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
NCT01709110 COMPLETED PHASE4
A Study of the Treatment of Postmenopausal Women With Osteoporosis
NCT00543023 COMPLETED PHASE3
Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis
NCT01535027 COMPLETED PHASE4
Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
NCT00532545 COMPLETED PHASE4
Alendronate and/or Parathyroid Hormone for Osteoporosis
NCT00000400 COMPLETED PHASE2
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
NCT03623633 UNKNOWN PHASE4